Ozempic (semaglutide) changes how your body handles blood sugar, hunger, digestion, and fat storage. It mimics a natural gut hormone called GLP-1 that your intestines release after you eat, but it lasts far longer in the body than the natural version. That extended activity triggers a cascade of effects across multiple organ systems, from your pancreas to your brain.
How It Affects Blood Sugar
Your pancreas is the first major target. Ozempic prompts it to release more insulin when blood sugar rises after a meal, which pulls glucose out of your bloodstream and into cells. At the same time, it suppresses glucagon, a hormone that tells your liver to dump stored sugar into your blood. The net result is lower blood sugar after eating without the wild spikes that damage blood vessels over time.
One important distinction: Ozempic only boosts insulin when blood sugar is actually elevated. Unlike injected insulin, which works regardless of glucose levels, this glucose-dependent action means the risk of dangerously low blood sugar (hypoglycemia) is much lower. That safety margin is a major reason it became a first-line option for type 2 diabetes.
What Happens in Your Brain
The drug crosses into the brain, where it targets appetite-regulating neurons in the hypothalamus. Research from Northwestern University has mapped out a two-pronged mechanism. First, Ozempic activates brainstem neurons that signal fullness, the same ones that fire when your stomach stretches after a large meal. Second, it silences a group of neurons called AgRP neurons that normally ramp up hunger when you’re losing weight.
That second effect matters more than it might sound. When anyone loses weight through dieting, AgRP neurons become increasingly active, driving the rebound hunger that makes sustained weight loss so difficult. Ozempic suppresses that compensatory hunger signal. As one researcher described it, you get a “double whammy” of feeling full while also blocking the biological alarm that would normally scream at you to eat because your body is shrinking. This is why people on the drug often describe a quiet indifference to food rather than willpower-driven restraint.
How Your Digestion Slows Down
Ozempic delays gastric emptying, meaning food sits in your stomach longer than usual before moving into the small intestine. This slower transit contributes to the feeling of prolonged fullness after meals and blunts the glucose spike that normally follows eating. The effect is most pronounced in the first hour after a meal and is strongest after your very first dose. Over weeks of continued treatment, this slowing effect partially fades as your body adjusts, a process called tachyphylaxis. Some studies suggest gastric emptying may be impaired for up to eight weeks.
This digestive slowdown is also the primary source of side effects. Nausea, vomiting, diarrhea, abdominal pain, and constipation are the most common, each reported in 5% or more of patients in clinical trials. The nausea tends to be worst during the early weeks and during dose increases, which is why prescribers start with a low, non-therapeutic dose of 0.25 mg weekly for four weeks before gradually stepping up. The maximum dose is 2 mg once weekly. About 3% to 4% of patients in trials stopped taking the drug because of gut-related side effects.
Weight Loss and Body Composition
In the landmark STEP 1 trial, people taking semaglutide at the higher weight-loss dose lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% in the placebo group. For someone weighing 220 pounds, that translates to roughly 33 pounds.
Not all of that lost weight is fat, and this is where the picture gets more complicated. Data from the same trial showed that out of every 15.3 kg lost, about 6.9 kg came from lean mass, which includes muscle. That means roughly 45% of the weight lost was not fat. This exceeded what researchers call the “quarter fat-free mass rule,” which predicts that about one-fourth of weight loss typically comes from lean tissue. Losing muscle at a higher-than-expected rate is a legitimate concern, particularly for older adults, because muscle mass protects joints, supports balance, and drives metabolic rate. Resistance training during treatment is the main strategy to counteract this.
Cardiovascular Effects
Beyond blood sugar and weight, Ozempic appears to protect the heart and blood vessels in ways that go beyond simply making people lighter. The SELECT trial, one of the largest cardiovascular outcome studies of its kind, found that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo in people with pre-existing heart disease and obesity who did not have diabetes. That reduction was significant enough to shift how cardiologists think about treating cardiovascular risk in people with obesity.
The Thyroid Safety Signal
Ozempic carries a boxed warning, the FDA’s most serious label alert, related to thyroid tumors. In rodent studies, semaglutide caused thyroid C-cell tumors at doses comparable to what humans take, and the risk increased with both dose and duration. Whether this translates to humans remains unknown, and the FDA states directly that “human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.”
Because of this uncertainty, the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to be aware of include a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness. Routine screening with thyroid ultrasound or blood calcitonin levels is not currently recommended for all patients on the drug, partly because these tests produce too many false positives given how common benign thyroid nodules are in the general population.
How the Dose Ramps Up
Ozempic is a once-weekly injection, and the dosing schedule is designed to let your body acclimate gradually. You start at 0.25 mg weekly for four weeks. That starting dose is not strong enough to produce a therapeutic effect on blood sugar; it exists solely to reduce the intensity of nausea and other digestive side effects. After four weeks, the dose moves to 0.5 mg, which is the first therapeutic level. From there, your prescriber may increase to 1 mg and eventually to the 2 mg maximum, depending on how your blood sugar and body respond. Each step up can temporarily bring back nausea, though for most people it settles within a few weeks at the new dose.